Arsen Valeryevich Volkov

Title: Arsen Valeryevich Volkov: Innovator in T Cell Receptor Technology

Introduction

Arsen Valeryevich Volkov is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of immunology, particularly in the development of T cell receptor (TCR) technologies. With a total of 3 patents, his work has the potential to advance therapeutic strategies in cancer treatment.

Latest Patents

Volkov's latest patents include innovative advancements in TCR libraries and T cell receptors. One of his patents focuses on a library of particles that display a variety of T cell receptors, which are essential for immune response. This library consists of TCRs with specific alpha and beta chain variable domains, designed to enhance the specificity and efficacy of T cell responses. Another significant patent involves T cell receptors that bind to the HLA-A*02 restricted peptide GLYDGMEHL, derived from the MAGE-A10 protein. These TCRs exhibit excellent specificity profiles for this MAGE epitope, and the patent also covers nucleic acids encoding these TCRs, engineered cells, and pharmaceutical compositions.

Career Highlights

Throughout his career, Volkov has worked with prominent companies in the biotechnology sector, including Immunocore Limited and Adaptimmune Limited. His experience in these organizations has allowed him to collaborate on cutting-edge research and development projects aimed at improving cancer immunotherapies.

Collaborations

Volkov has collaborated with notable professionals in the field, including Peter Eamon Molloy and Dhaval Jaykant Sangani. These collaborations have contributed to the advancement of TCR technology and its applications in therapeutic settings.

Conclusion

Arsen Valeryevich Volkov is a distinguished inventor whose work in T cell receptor technology is paving the way for innovative cancer treatments. His patents and collaborations reflect his commitment to advancing immunological research and improving patient outcomes.